SAB Biotherapeutics
SABS
SABS
26 hedge funds and large institutions have $2.99M invested in SAB Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
70% less capital invested
Capital invested by funds: $10.1M → $2.99M (-$7.12M)
Holders
26
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$35.1K | |
| 2 | +$29.9K | |
| 3 | +$22.3K | |
| 4 |
Renaissance Technologies
New York
|
+$13.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.01K |
Top Sellers
| 1 | -$1.75M | |
| 2 | -$114K | |
| 3 | -$17.6K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.37K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.09K |
